as of —
₹—
Change
—
Day Open
₹—
Day High
₹—
Day Low
₹—
NSE Close — 19 Nov 2026
₹9.98
Change
-0.01 (-0.1%)
Open
₹9.86
Prev. Close
₹9.99
Day High
₹10.28
Day Low
₹9.85
Volume Analysis
Traded
126,918
Delivered
109,032
Delivery %
85.91%
End-of-day NSE price via the official Bhavcopy — updated once daily after market close, not a live tick.
Strengths, Weaknesses, Opportunities & Threats
Strengths (0)
No signal for this stock
Weaknesses (4)
- •Low return on equity (-31.3%)
- •Promoter holding is falling
- •Below-average fundamentals quality score (28/100)
- •Low operating margin (-5352.0%)
Opportunities (0)
No signal for this stock
Threats (1)
- •FII holding has been falling
Rule-based signals from the fundamentals below — not investment advice.
Pivot Levels
| Type | R3 | R2 | R1 | Pivot | S1 | S2 | S3 |
|---|---|---|---|---|---|---|---|
| Classic | ₹10.66 | ₹10.47 | ₹10.23 | ₹10.04 | ₹9.8 | ₹9.61 | ₹9.37 |
| Fibonacci | ₹10.47 | ₹10.31 | ₹10.2 | ₹10.04 | ₹9.88 | ₹9.77 | ₹9.61 |
| Camarilla | ₹10.1 | ₹10.06 | ₹10.02 | ₹10.04 | ₹9.94 | ₹9.9 | ₹9.86 |
Support/resistance levels for today, calculated from the previous trading day's high/low/close.
Absolute Returns
YTD
-51.03%
1 Week
-4.59%
1 Month
-11.6%
3 Months
-4.68%
6 Months
-17.25%
1 Year
-29.57%
2Y/3Y/5Y not shown yet — price history tracking only goes back to mid-2025 so far.
Stock Vitals
Computed from the latest available annual financials.
DuPont ROE Breakdown
-0.0%
Net margin -3300.0% × asset turnover 0.0x × equity multiplier 1.06x
Company Overview
Sector
Healthcare
Market Cap
₹193 Cr
ROE
-31.3%
Book Value
₹29.3
Face Value
₹1.0
Source: Screener.in (Consolidated figures) — data as of 19 Nov 2026. Not investment advice.
TopFund Analysis
Nectar Lifesciences Ltd. scores weakly on TopFund's composite fundamentals check within the Healthcare sector, at 28/100. The strongest factor is Financial Strength (100/100), while Growth (0/100) is the weakest area to weigh before deciding. Notably: Low return on equity (-31.3%); promoter holding is falling. FII holding has been falling.
TopFund Score — Fundamentals Quality
28/100 — WeakData confidence: 75/100 (Moderate Confidence) — based on how complete and how fresh the underlying data is.
As of 19 Nov 2026 · How we calculate this →
Financial Strength
Growth
Valuation
Cash Flow
Corporate Governance
Momentum
Institutional Ownership
Business Quality
Risk & Volatility
Liquidity
From Screener.in
- +Company has reduced debt.
- +Company is almost debt free.
- +Stock is trading at 0.34 times its book value
- −Company has low interest coverage ratio.
- −Company has a low return on equity of -12.3% over last 3 years.
- −Contingent liabilities of Rs.269 Cr.
- −Promoter holding has decreased over last 3 years: -3.96%
Not investment advice — an automated read of public fundamentals data, for research context only.
Corporate Actions
Nectar Lifesciences Limited has informed about Copy of Newspaper Publication
Please find attached herewith certificate as per caption regulations
31st AGM minutes: FY26 financials adopted; Sanjiv Goyal reappointed; two independent directors reappointed; Dr. Gunmala Suri appointed.
Source: BSE regulatory filings, via Screener.in.
Quarterly Results
Last several quarters
| Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales + | 398 | 452 | 441 | 359 | 6 | 0 | 0 | 5 | 1 | 0 | 1 | 0 | 0 |
| Expenses + | 371 | 410 | 393 | 319 | 6 | 0 | 0 | 6 | 0 | 2 | 59 | 28 | 7 |
| Operating Profit | 27 | 42 | 49 | 40 | -1 | 0 | 0 | -1 | 1 | -2 | -57 | -27 | -7 |
| OPM % | 6.75% | 9.33% | 10.99% | 11.08% | -10.28% | -500.0% | -500.0% | -16.03% | 77.46% | — | -4,437.21% | -6,197.73% | -66,800.0% |
| Other Income + | 11 | 0 | 1 | 1 | 7 | 8 | -130 | -62 | -176 | 35 | -24 | 3 | 13 |
| Interest | 21 | 25 | 24 | 20 | 0 | 0 | 0 | 0 | 0 | 30 | 6 | 0 | 0 |
| Depreciation | 15 | 15 | 15 | 15 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 |
| Profit before tax | 2 | 2 | 11 | 5 | 5 | 8 | -130 | -64 | -176 | 3 | -88 | -24 | 6 |
| Tax % | 38.41% | 36.18% | 94.69% | 39.63% | -2.19% | 1.51% | -0.05% | -0.58% | 0.09% | -339.08% | -22.5% | -36.63% | 57.7% |
| Net Profit + | 1 | 2 | 1 | 3 | 6 | 8 | -130 | -63 | -176 | 14 | -68 | -15 | 3 |
| EPS in Rs | 0 | 0 | 0 | 0 | 0 | 0 | -6 | -3 | -8 | 1 | -4 | -1 | 0 |
| Raw PDF | — | — | — | — | — | — | — | — | — | — | — | — | — |
| YoY Sales growth | 2 | 31 | 14 | -9 | -99 | -100 | -100 | -99 | -88 | -100 | 12,800 | -92 | -99 |
Source: Screener.in — figures in ₹ Crores unless marked %.
Profit & Loss (Yearly)
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales + | 1,638 | 1,674 | 1,635 | 1,874 | 2,779 | 2,363 | 1,541 | 1,665 | 1,520 | 1,682 | 0 | 0 | 2 |
| Expenses + | 1,371 | 1,436 | 1,411 | 1,638 | 2,514 | 2,143 | 1,432 | 1,507 | 1,467 | 1,530 | 0 | 8 | 95 |
| Operating Profit | 267 | 239 | 224 | 236 | 264 | 220 | 109 | 159 | 53 | 152 | 0 | -8 | -93 |
| OPM % | 16.0% | 14.0% | 14.0% | 13.0% | 10.0% | 9.0% | 7.0% | 10.0% | 3.5% | 9.0% | -12.0% | -2,920.0% | -5,352.0% |
| Other Income + | 20 | 6 | 23 | 6 | 6 | 4 | -22 | 11 | 43 | 15 | -112 | -279 | 28 |
| Interest | 126 | 123 | 117 | 115 | 148 | 126 | 112 | 79 | 79 | 87 | 0 | 36 | 36 |
| Depreciation | 77 | 57 | 62 | 64 | 63 | 61 | 60 | 57 | 59 | 61 | 1 | 0 | 0 |
| Profit before tax | 85 | 64 | 67 | 63 | 59 | 37 | -85 | 34 | -42 | 18 | -113 | -323 | -102 |
| Tax % | 22.0% | 15.0% | 18.0% | 17.0% | 19.0% | 15.0% | -14.0% | 26.0% | -43.0% | 73.0% | 0.0% | -9.0% | — |
| Net Profit + | 66 | 54 | 55 | 52 | 48 | 32 | -73 | 25 | -24 | 5 | -114 | -293 | -66 |
| EPS in Rs | 3 | 2 | 2 | 2 | 2 | 1 | -3 | 1 | -1 | 0 | -5 | -15 | -4 |
| Dividend Payout % | 3.0% | 4.0% | 2.0% | 2.0% | 2.0% | 4.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — |
| Sales growth | 0 | 2 | -2 | 15 | 48 | -15 | -35 | 8 | -9 | 11 | -100 | — | -71 |
Source: Screener.in — figures in ₹ Crores unless marked %.
Balance Sheet
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | Sep 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reserves | 936 | 932 | 984 | 1,036 | 1,083 | 1,114 | 1,040 | 1,065 | 1,042 | 1,047 | 934 | 563 | 550 |
| Borrowings + | 925 | 962 | 878 | 955 | 903 | 779 | 903 | 860 | 754 | 636 | 582 | 0 | 0 |
| Other Liabilities + | 628 | 640 | 696 | 710 | 696 | 718 | 423 | 443 | 371 | 486 | 509 | 39 | 32 |
| Total Liabilities | 2,510 | 2,556 | 2,581 | 2,724 | 2,705 | 2,633 | 2,388 | 2,391 | 2,189 | 2,191 | 2,047 | 622 | 601 |
| Fixed Assets + | 934 | 906 | 881 | 852 | 825 | 785 | 772 | 723 | 662 | 643 | 633 | 105 | 105 |
| CWIP | 91 | 99 | 102 | 100 | 100 | 115 | 99 | 85 | 78 | 66 | 57 | 0 | 0 |
| Investments | 1 | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 1 | 13 | 56 |
| Other Assets + | 1,485 | 1,551 | 1,597 | 1,771 | 1,780 | 1,733 | 1,517 | 1,582 | 1,449 | 1,482 | 1,357 | 504 | 441 |
| Total Assets | 2,510 | 2,556 | 2,581 | 2,724 | 2,705 | 2,633 | 2,388 | 2,391 | 2,189 | 2,191 | 2,047 | 622 | 601 |
| Equity Capital | 22 | 22 | 22 | 22 | 22 | 22 | 22 | 22 | 22 | 22 | 22 | 19 | 19 |
Source: Screener.in — figures in ₹ Crores unless marked %.
Cash Flow
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operating Activity + | 144 | 169 | 199 | 65 | 239 | 285 | 21 | 95 | 134 | 225 | 169 | -349 |
| Cash from Investing Activity + | -60 | -77 | -18 | -29 | -26 | -33 | -29 | 17 | 52 | -17 | -42 | 1,208 |
| Cash from Financing Activity + | -61 | -89 | -204 | -40 | -201 | -252 | 11 | -119 | -186 | -205 | -128 | -767 |
| Net Cash Flow | 23 | 3 | -23 | -4 | 12 | 0 | 4 | -8 | 0 | 2 | -1 | 93 |
| Free Cash Flow | 64 | 87 | 174 | 32 | 204 | 249 | -10 | 110 | 183 | 195 | 126 | -341 |
| CFO/EBITDA Share of operating profit converting into cash: CFO (before tax) / Operating Profit | 56 | 74 | 92 | 33 | 96 | 134 | 23 | 60 | 252 | 148 | -89,179 | 4,132 |
Source: Screener.in — figures in ₹ Crores unless marked %.
Shareholding Pattern
Quarter-by-quarter — Promoters, FII, DII & public holding trend
| Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Public | 28.05% | 27.2% | 27.57% | 40.94% | 54.72% | 53.64% | 54.45% | 54.37% | 48.73% | 43.52% | 43.9% | 43.74% |
| Promoters | 55.8% | 55.8% | 55.8% | 55.8% | 44.53% | 44.53% | 44.53% | 44.91% | 44.91% | 51.84% | 51.84% | 51.84% |
| Government | 0.02% | 0.02% | 0.02% | 0.02% | 0.02% | 0.02% | 0.02% | 0.02% | 5.84% | 4.03% | 3.75% | 3.92% |
| FII | 16.12% | 16.98% | 16.6% | 3.24% | 0.73% | 1.65% | 0.82% | 0.62% | 0.52% | 0.6% | 0.5% | 0.5% |
| DII | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.15% | 0.19% | 0.08% | 0.0% | 0.01% | 0.01% | 0.0% |
Source: Screener.in — quarterly shareholding disclosures.
Peers Comparison
Healthcare — ranked by market cap
| Company | Market Cap (Cr) | P/E | P/B | ROE |
|---|---|---|---|---|
| Nectar Lifesciences Ltd. (this stock) | 193 | — | 0.34 | -31.3% |
| Take Limited | 192 | 22.0 | 5.6 | 16.5% |
| Bilcare Ltd. | 202 | 5.55 | 1.13 | 1.39% |
| Brooks Lab Limited | 203 | 58.7 | 1.08 | 22.0% |
| Balaxi Pharma Ltd | 175 | 51.8 | 0.69 | 0.59% |
| Makers Laboratories Ltd. | 169 | 22.6 | 2.15 | 3.17% |
| Natural Capsules Limited | 144 | — | 0.66 | -9.45% |
Which Mutual Funds Hold Nectar Lifesciences Ltd.?
Frequently Asked Questions about Nectar Lifesciences Ltd.
Nectar Lifesciences Ltd. (NECLIFE) closed at ₹9.98 on NSE on 19 November 2026, down 0.01 (0.1%) from the previous close.
Nectar Lifesciences Ltd. trades on the NSE (National Stock Exchange of India) under the symbol NECLIFE.
Nectar Lifesciences Ltd. has a dividend yield of 0.0%.
Nectar Lifesciences Ltd.'s 52-week high is ₹22.5 and its 52-week low is ₹9.2.
Nectar Lifesciences Ltd. has a market capitalisation of ₹193 crore.
Nectar Lifesciences Ltd. has a TopFund Quality Score of 28/100 (Weak), a composite of profitability, balance-sheet health, growth and valuation. This is an analytical score based on public data, not personalized investment advice — see the full breakdown below before deciding.
Community Sentiment
What are other investors saying about Nectar Lifesciences Ltd.?
No votes yet — be the first to share your view.
Sign in to voteDiscussion
User-generated content — not investment advice, and not verified or endorsed by TopFund.
Sign in to join the discussionNo comments yet — start the discussion.